AstraZeneca PLC (AZN) paid $3.20 in dividends per share over the trailing twelve months. The 5-year dividend CAGR is +2.47%.
AZN Annual Dividends per Share (Dividend History)
This step chart displays the nominal dividend payouts over time on their actual payment dates, matching the distribution frequency (typically quarterly or semi-annually).
Annual Dividend History List
| Payment Date | Nominal Dividend / Share | Distribution Change |
|---|---|---|
| Feb 20, 2026 | $2.17 | +110.68% Hike |
| Aug 8, 2025 | $1.03 | -51.60% Cut |
| Feb 21, 2025 | $2.13 | +112.81% Hike |
| Aug 9, 2024 | $1.00 | -49.24% Cut |
| Feb 22, 2024 | $1.97 | +111.83% Hike |
| Aug 10, 2023 | $0.93 | -52.79% Cut |
| Feb 23, 2023 | $1.97 | +111.43% Hike |
| Aug 11, 2022 | $0.93 | -52.70% Cut |
| Feb 24, 2022 | $1.97 | +119.75% Hike |
| Aug 12, 2021 | $0.90 | -53.83% Cut |
| Feb 25, 2021 | $1.94 | +113.06% Hike |
| Aug 13, 2020 | $0.91 | -51.64% Cut |
| Feb 27, 2020 | $1.88 | +116.03% Hike |
| Aug 8, 2019 | $0.87 | -54.08% Cut |
| Feb 28, 2019 | $1.90 | +111.11% Hike |
| Aug 9, 2018 | $0.90 | -52.63% Cut |
| Feb 15, 2018 | $1.90 | +111.11% Hike |
| Aug 9, 2017 | $0.90 | -52.63% Cut |
| Feb 15, 2017 | $1.90 | +111.11% Hike |
| Aug 10, 2016 | $0.90 | -52.63% Cut |
| Feb 17, 2016 | $1.90 | +111.11% Hike |
| Aug 12, 2015 | $0.90 | -52.63% Cut |
| Feb 18, 2015 | $1.90 | +111.11% Hike |
| Aug 13, 2014 | $0.90 | -52.63% Cut |
| Feb 19, 2014 | $1.90 | +111.11% Hike |
| Aug 14, 2013 | $0.90 | -52.63% Cut |
| Feb 13, 2013 | $1.90 | +111.11% Hike |
| Aug 8, 2012 | $0.90 | -53.85% Cut |
| Feb 15, 2012 | $1.95 | +129.41% Hike |
| Aug 4, 2011 | $0.85 | -54.05% Cut |
| Feb 2, 2011 | $1.85 | +164.29% Hike |
| Aug 4, 2010 | $0.70 | -59.06% Cut |
| Feb 3, 2010 | $1.71 | +189.83% Hike |
| Aug 5, 2009 | $0.59 | -60.67% Cut |
| Feb 4, 2009 | $1.50 | +172.73% Hike |
| Aug 6, 2008 | $0.55 | -59.26% Cut |
| Feb 7, 2008 | $1.35 | +159.62% Hike |
| Aug 8, 2007 | $0.52 | -57.72% Cut |
| Feb 7, 2007 | $1.23 | +151.02% Hike |
| Aug 9, 2006 | $0.49 | -46.74% Cut |
| Feb 8, 2006 | $0.92 | +142.11% Hike |
| Aug 10, 2005 | $0.38 | -41.09% Cut |
| Feb 9, 2005 | $0.65 | +118.64% Hike |
| Aug 11, 2004 | $0.29 | -45.37% Cut |
| Feb 18, 2004 | $0.54 | +111.76% Hike |
| Aug 20, 2003 | $0.26 | -51.17% Cut |
| Feb 19, 2003 | $0.52 | +104.35% Hike |
| Aug 21, 2002 | $0.26 | -51.06% Cut |
| Feb 20, 2002 | $0.52 | +104.38% Hike |
| Aug 22, 2001 | $0.26 | -51.07% Cut |
| Feb 21, 2001 | $0.52 | -51.33% Cut |
| Nov 14, 2000 | $1.07 | +319.96% Hike |
| Sep 6, 2000 | $0.26 | -51.07% Cut |
| Mar 8, 2000 | $0.52 | +104.38% Hike |
| Sep 8, 1999 | $0.26 | -48.45% Cut |
| Apr 7, 1999 | $0.50 | +75.12% Hike |
| Sep 16, 1998 | $0.28 | -44.73% Cut |
| Mar 18, 1998 | $0.51 | +92.24% Hike |
| Sep 17, 1997 | $0.27 | -40.46% Cut |
| Mar 19, 1997 | $0.45 | +85.87% Hike |
| Sep 20, 1996 | $0.24 | -5.00% Cut |
| Mar 22, 1996 | $0.25 | +13.26% Hike |
| Sep 22, 1995 | $0.22 | -36.22% Cut |
| Mar 24, 1995 | $0.35 | +70.78% Hike |
| Sep 23, 1994 | $0.21 | -34.68% Cut |
| Mar 18, 1994 | $0.31 | +62.87% Hike |
| Sep 24, 1993 | $0.19 | — |
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot